Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 - DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad

The Key Migraine Companies in the market include - Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others.
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Migraine Market Report:

*
The Migraine market size was valued ~USD 10.8 billion in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In January 2026, Teva Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY Registered (fremanezumab) for the preventive treatment of episodic migraine in pediatric patients aged 6 to 17 years who weigh at least 45 kg (99 pounds). With this approval, AJOVY becomes the first calcitonin gene-related peptide (CGRP) antagonist indicated for migraine prevention in both adults and children. The decision is supported by positive findings from the Phase 3 SPACE trial, which showed that AJOVY significantly reduced the number of monthly migraine and headache days compared with placebo over a 12-week period in pediatric patients with episodic migraine. The study enrolled 237 participants and demonstrated a safety profile consistent with previous adult trials. This milestone addresses a critical unmet need in pediatric migraine care, as approximately one in ten children and adolescents experience migraines, often affecting their academic performance, daily functioning, and overall quality of life.

*
In January 2026, Fremanezumab-vfrm (Ajovy) showed a statistically significant decrease in both monthly migraine days and monthly headache days of at least moderate severity compared with placebo. Results from the Phase III SPACE trial (NCT04458857) formed the basis for the recent FDA approval of the therapy for preventing episodic migraine in children and adolescents aged 6 to 17 years.

*
In September 2025, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. have announced that the first patient has been enrolled and dosed in the KOMET-017 study. This program consists of two separate global Phase 3, randomized, double-blind, placebo-controlled trials designed to assess ziftomenib an investigational menin inhibitor developed by Kura Oncology. The trials will evaluate ziftomenib in combination with both intensive and less intensive treatment regimens in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia.

*
In September 2025, ShiraTronics is targeting U.S. FDA approval for its migraine implant by 2027, followed by a regulatory review in Australia. The ShiraTronics Migraine Therapy System is a fully implantable neuromodulation device developed specifically for treating migraine with a head-focused approach. In contrast to earlier off-label applications of spinal cord stimulators, the system uses subcutaneous leads positioned to stimulate the occipital and supraorbital nerves.

*
In September 2025, Click Therapeutics, Inc., a leader in Digital Therapeutics Trademark , announced that it met the primary endpoint in its pivotal randomized, double-blind, controlled, decentralized ReMMi-D trial (NCT05853900) evaluating CT-132 for migraine prevention. Following 12 weeks of treatment, CT-132 achieved a statistically significant reduction in monthly migraine days (MMDs) compared with the sham control, showing a difference of -0.9 MMDs (p=0.005) in the intent-to-treat (ITT) population of 568 participants. By the end of the study, patients receiving CT-132 experienced an average decrease of -3.04 monthly migraine days.

*
In June 2025, Lundbeck's humanized monoclonal antibody, Vyepti (eptinezumab), successfully achieved both primary and secondary endpoints in the placebo-controlled, randomized Phase IV RESOLUTION trial involving patients with chronic migraine and coexisting medication-overuse headache (MOH), who also received standardized patient education. The study enrolled 608 participants diagnosed with both chronic migraine and MOH, who were randomly assigned to receive either eptinezumab with a brief educational intervention (BEI) or placebo with BEI. The primary objective was to evaluate the reduction in monthly migraine days (MMDs) from baseline during the first four weeks of treatment.

*
In June 2025, AbbVie announced that its Phase III TEMPLE study, comparing the oral CGRP receptor antagonist atogepant to the highest tolerated dose of topiramate for adult migraine, has successfully met its primary endpoint. This double-blind, randomized, head-to-head trial demonstrated that atogepant resulted in fewer treatment discontinuations due to adverse events (AEs) compared to topiramate. The study included participants with a history of four or more migraine days per month.

*
In February 2025, Results from the Phase III EMERGE trial (NCT05550207) indicate that Symbravo (MoSEIC meloxicam and rizatriptan; Axsome Therapeutics) significantly outperformed oral calcitonin gene-relat ed peptide (CGRP) inhibitors in terms of migraine treatment response, pain relief, and quality of life among patients who had previously shown inadequate response to CGRPs. Trial investigators noted that these outcomes suggest Symbravo offers faster and more sustained pain relief, addressing the unmet need for effective migraine treatment options in this patient population.

*
In December 2024, Teva Pharmaceutical Industries has announced positive results from its multicenter Phase III SPACE trial evaluating Ajovy (fremanezumab) as a preventive treatment for episodic migraine in children and adolescents aged 6 to 17 years. This double-blind, parallel-group, randomized, placebo-controlled study showed a statistically significant decrease in migraine frequency over 12 weeks compared to placebo, with a safety profile consistent with that seen in adult patients.

*
In 2023, the US had the largest market size for Migraine among the 7MM, totaling approximately USD 6,790 million. This figure is projected to rise further by 2034.

*
In 2023, the market size for episodic migraine (comprising preventive and acute treatments) in the US was approximately USD 4,026 million, while for chronic migraine (including preventive and acute treatments), it was nearly USD 2,766 million in the same year.

*
In 2023, the highest patient share of Migraine in the 7MM was observed in the US, comprising 39% of the total cases, followed by Japan with approximately 14%. In European nations, the UK reported a higher number of cases, representing about 11% of the total 7MM cases.

*
In 2023, the estimated prevalent population of Migraine in the 7MM was approximately 119,233 cases.

*
The total prevalent cases of Migraine in the US are projected to see a notable Compound Annual Growth Rate (CAGR) by 2034, rising from approximately 46,140 cases in 2023.

*
In 2023, Germany reported the highest prevalent population of Migraine among European countries, accounting for 22%, followed by Italy. Conversely, Spain had the lowest prevalent population of Migraine, representing around 17% in the same year.

*
In Japan, the majority of prevalent Migraine cases in 2023 were categorized as Episodic Migraine, totaling approximately 16,331 cases. Conversely, the least prevalent cases were classified as Chronic Migraine, numbering around 950 cases in the same year.

*
According to analyses by DelveInsight's experts, the majority of Migraine cases are observed in females compared to males. In 2023, there were approximately 11,535 thousand male cases and around 34,605 thousand female cases of Migraine in the US.

*
In the EU4 and the UK, the majority of diagnosed cases of Migraine in 2023 were categorized as Episodic Migraine, totaling approximately 15,839 thousand cases. Conversely, the least diagnosed cases were identified as Chronic Migraine, numbering around 2,411 thousand in the same year.

*
Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

*
Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), AXS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others

*
The Migraine epidemiology based on gender analyzed that females experience a more significant impact in relation to Migraine compared to males

*
The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.

Migraine Overview

Migraine is a neurological condition characterized by intense, debilitating headaches often accompanied by other symptoms. Migraines can significantly affect a person's quality of life, with varying frequency and severity from person to person.

Get a Free sample for the Migraine Market Report

https://www.delveinsight.com/report-store/migraine-market [https://www.delveinsight.com/report-store/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Migraine Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Migraine Epidemiology Segmentation:

The Migraine market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Migraine

*
Prevalent Cases of Migraine by severity

*
Gender-specific Prevalence of Migraine

*
Diagnosed Cases of Episodic and Chronic Migraine

Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Migraine Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Migraine Therapies and Key Companies

*
EMGALITY (Galcanezumab-gnlm): Eli Lilly and Company

*
AJOVY (fremanezumab-vfrm): Teva Pharmaceuticals

*
AXS-07: Axsome Therapeutics

*
ABP-450: AEON Biopharma, Inc.

*
Aimovig: Amgen

*
CL-H1T: Charleston Laboratories

*
AIMOVIG: Amgen

*
Fremanezumab: Teva Pharmaceuticals

*
Galcanezumab: Eli Lilly and Company

*
propranolol LA: Anne Lindblad

*
Atogepant: Allergan

*
LBR-101: Teva Branded Pharmaceutical

*
Atogepant: AbbVie

*
Galcanezumab: Eli Lilly and Company

*
Marcaine: Tian Medical Inc.

*
Atogepant: Allergan

*
Galcanezumab: Eli Lilly and Company

*
Eptinezumab: H. Lundbeck A/S

*
TNX-1900: Tonix Pharmaceuticals, Inc.

*
IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.

Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Migraine Market Drivers

*
Rising Global Prevalence of Migraine: Increasing incidence across all age groups, especially among women, is expanding the patient pool worldwide.

*
Growing Awareness and Early Diagnosis: Improved patient education and better access to neurologists are leading to higher diagnosis and treatment rates.

*
Advancements in Targeted Therapies (CGRP Inhibitors): The launch and adoption of CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and oral gepants are transforming preventive and acute migraine treatment.

*
Strong R&D Pipeline: Ongoing development of next-generation gepants, ditans, neuromodulation devices, and combination therapies is fueling market growth.

Migraine Market Barriers

*
High Cost of Biologic Therapies: CGRP inhibitors and novel agents are expensive, limiting accessibility in cost-sensitive markets.

*
Reimbursement Challenges: Strict insurance criteria and step-therapy requirements delay access to advanced treatments.

*
Side Effects and Safety Concerns: Long-term safety data for newer biologics is still evolving, affecting physician confidence in some cases.

*
Underdiagnosis and Misdiagnosis: Many migraine sufferers remain untreated or self-medicate without professional consultation.

Scope of the Migraine Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Migraine Companies: Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories, Amgen, Teva Pharma, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie, Tian Medical Inc., Allergan, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others

*
Key Migraine Therapies: EMGALITY (Galcanezumab-gnlm), AJOVY (fremanezumab-vfrm), XS-07, ABP-450, Aimovig, CL-H1T, AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others

*
Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies

*
Migraine Market Dynamics: Migraine market drivers and Migraine market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Migraine Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement

To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Migraine Market Report Introduction

2. Executive Summary for Migraine

3. SWOT analysis of Migraine

4. Migraine Patient Share (%) Overview at a Glance

5. Migraine Market Overview at a Glance

6. Migraine Disease Background and Overview

7. Migraine Epidemiology and Patient Population

8. Country-Specific Patient Population of Migraine

9. Migraine Current Treatment and Medical Practices

10. Migraine Unmet Needs

11. Migraine Emerging Therapies

12. Migraine Market Outlook

13. Country-Wise Migraine Market Analysis (2020-2034)

14. Migraine Market Access and Reimbursement of Therapies

15. Migraine Market Drivers

16. Migraine Market Barriers

17. Migraine Appendix

18. Migraine Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=migraine-market-pharma-pipeline-fuels-rapid-expansion-by-2034-delveinsight-eli-lilly-and-company-axsome-therapeutics-aeon-biopharma-charleston-laboratories-amgen-teva-pharma-anne-lindblad]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.